explore -WSS

explore

author：explore 2025-10-01 21:40:05 - browse：5

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

WSS

In the gardens at Boston Children's Hospital, families find sanctuary

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Truvian presents data for its desktop blood

Biden warns of ‘dark winter’ during final presidental debate

Will the FTC rein in IQVIA's health data empire?

'Investigate these claims': UFO transparency at center of House hearing

leisure time

explore

explore

Supreme Court strikes down use of affirmative action

Why patients can’t get everything they want on drug pricing

23andMe had bad news about my health. I wish a person had delivered it

How doctors’ personal politics affect patients

As demand for Covid shots wanes, Moderna seeks its next success

Dems pitch expanding Medicare power to negotiate drug prices

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Millions may soon lose Medicaid when they don't have to

At least 13 dead in Texas as scorching temps continue

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

hotspot

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Rise in cancer among younger people worries and puzzles doctors

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Biogen nominates mother of director’s child to replace him on board

Senate panel puts off hardest PBM reforms for another day

UHS says company favors patients whose insurance pays more

explore

leisure time

Wikipedia

knowledge